{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:46:11Z","timestamp":1785757571468,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijantimicag.2026.107740","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:58:30Z","timestamp":1770883110000},"page":"107740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2300-048X","authenticated-orcid":false,"given":"Yury A.","family":"Surovoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-7343","authenticated-orcid":false,"given":"Inna A.","family":"Galvidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-3899","authenticated-orcid":false,"given":"Akmal I.","family":"Alimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei V.","family":"Tsarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1946-430X","authenticated-orcid":false,"given":"Maksim A.","family":"Burkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107740_bib0001","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0002","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0003","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","article-title":"Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet?","volume":"48","author":"Tran","year":"2016","journal-title":"Int J Antimicrobl Agents"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0004","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12879-023-08339-0","article-title":"Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0006","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/jac\/dks437","article-title":"Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis","volume":"68","author":"Sandri","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01475-17","article-title":"Population pharmacokinetics of polymyxin B in acutely ill adult patients","volume":"62","author":"Miglis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01493-17","article-title":"Population pharmacokinetics of intravenous polymyxin B from clinical samples","volume":"62","author":"Kubin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0009","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/phar.2129","article-title":"Polymyxin B pharmacokinetics in Adult cystic fibrosis patients","volume":"38","author":"Avedissian","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106599","article-title":"Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0011","first-page":"dkac021","article-title":"Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation","author":"Surovoy","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00228-022-03415-x","article-title":"Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis","volume":"79","author":"Surovoy","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106214","article-title":"Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy","volume":"175","author":"Luo","year":"2022","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0014","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-024-03666-w","article-title":"Pharmacokinetics of polymyxin B in different populations: a systematic review","volume":"80","author":"Wang","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fphar.2020.00829","article-title":"Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant Gram-negative bacterial infections","volume":"11","author":"Wang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00228-020-02986-x","article-title":"Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia","volume":"77","author":"Chen","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0017","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/jac\/dkad012","article-title":"Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients","volume":"78","author":"Pi","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0018","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114275","article-title":"Development of ELISA formats for polymyxin B monitoring in serum of critically ill patients","volume":"204","author":"Burkin","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0020","article-title":"Efficient PK modeling workflow with the MonolixSuite: a case study of remifentanil","volume":"9:198\u2013210","author":"Traynard","year":"2020","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114983","article-title":"Unbound serum polymyxin B in patients with sepsis: detection approaches and limited sampling strategy for clinical practice and research","volume":"220","author":"Galvidis","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0022","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0023","first-page":"1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper#","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0024","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/jac\/dkac291","article-title":"Assessment of current practice for \u03b2-lactam therapeutic drug monitoring in French ICUs in 2021: a nationwide cross-sectional survey","volume":"77","author":"Tritscher","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13613-021-00917-2","article-title":"Antimicrobial stewardship, therapeutic drug monitoring and infection management in the ICU: results from the international A- TEAMICU survey","volume":"11","author":"Lanckohr","year":"2021","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0026","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00134-025-07822-3","article-title":"Antibiotic dosing optimization in critically ill patients","volume":"51","author":"Koulenti","year":"2025","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0034-1398490","article-title":"Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development","volume":"36","author":"Abdul-Aziz","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0028","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41579-021-00578-9","article-title":"Optimizing antimicrobial use: challenges, advances and opportunities","volume":"19","author":"Rawson","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0029","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0000000000000572","article-title":"Pharmacokinetic characteristics and limited sampling strategies for therapeutic drug monitoring of colistin in patients with multidrug-resistant Gram-negative bacterial infections","volume":"41","author":"Kim","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0030","article-title":"Personalizing polymyxin B dosing using an adaptive feedback control algorithm","volume":"62:e00483\u201318","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0031","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0032","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.2147\/IDR.S486169","article-title":"Pharmacokinetic changes and influencing factors of polymyxin B in different ECMO modes","volume":"17","author":"Xu","year":"2024","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0033","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/jcpt.13711","article-title":"The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation","volume":"47","author":"Ye","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2026.107740_bib0034","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/pharmaceutics14112323","article-title":"Evaluation and validation of the limited sampling strategy of polymyxin B in patients with multidrug-resistant Gram-negative infection","volume":"14","author":"Li","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:02:51Z","timestamp":1785754971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0924857926000294"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107740","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107740"}}